The primary endpoints were the differences in forced vital capacity (ΔFVC) and the differences in forced expiratory volume in the first second (ΔFEV1) between the Spirofy™ and Vitalograph Alpha Touch™ spirometers. The co-primary endpoint was the difference in FEV1/FVC ratio of < 0.7 between the Spirofy™ and Vitalograph Alpha Touch™ spirometers. The distribution of the FEV1/FVC ratio < 0.7 was used to assess the diagnostic accuracies of the Spirofy™ devices by comparing their performance with that of the Vitalograph in being able to differentiate subjects with OAD from healthy individuals; the results have been presented as the sensitivity, specificity, and overall accuracy of each device.
Alpha touch
Manufactured by Vitalograph
Sourced in United Kingdom
The Vitalograph Alpha Touch is a compact and portable lung function testing device. It is designed to measure and record various pulmonary function parameters, including forced vital capacity (FVC), forced expiratory volume (FEV), and peak expiratory flow (PEF). The device features a touch screen interface for easy operation and data management.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using alpha touch
1
Comparison of Spirometry Devices
2
Assessment of Recovery from Acute Exacerbation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In this prospective study, participants were assessed on admission for demographic data, medical history and medications, symptoms and observations, blood tests, spirometry (Microlab 3500 (Carefusion, Hampshire, UK) or Vitalograph Alpha Touch (Vitalograph, Buckinghamshire, UK)) and fractional exhaled nitric oxide (NIOX MINO, Aerocrine, Solna, Sweden). Participants remained under the care of their own clinicians. Participants were discharged when they did not require supplemental oxygen, intravenous medication or nebulised bronchodilators and their peak flow had recovered to at least 75% of their normal. In view of a lack of standardised definition of recovery from acute exacerbation, participants were asked if they felt they had recovered to baseline at 4 weekly intervals after discharge.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!